首页> 外文OA文献 >A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

【2h】

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

机译：I / II剂量升级研究调查全口腔IXAZOMIB-MELPHALAN-PREDNNISONE诱导，然后是单体剂IXAZOMIB维持在移植术中新诊断的多发性骨髓瘤中

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Jesús F. San-Miguel; Maria-Asunción Echeveste Gutierrez; Ivan Špicka; María-Victoria Mateos; Kevin Song; Michael D. Craig; Joan Bladé; Roman Hájek; Christine Chen; Alessandra Di Bacco; Jose Estevam; Neeraj Gupta; Catriona Byrne; Vickie Lu; Helgi van de Velde; Sagar Lonial;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma [J] . Jesús F. San-Miguel, Maria-Asunción Echeveste Gutierrez, Ivan ?picka, Haematologica . 2018,第9期

机译：I / II期剂量递增研究，研究在不适合移植的新诊断多发性骨髓瘤中全口口服依沙米单抗-美法仑-泼尼松诱导后单药依沙米单抗维持
2. Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial [J] . Sonja Zweegman, Claudia A.M. Stege, Einar Haukas, Haematologica . 2020,第12期

机译：IXAZOMIB-羟胺胺 - 低剂量地塞米松诱导随后与新诊断的多发性骨髓瘤患者的IXAZOMIB或安慰剂进行维持治疗，没有资格获得自体干细胞移植;随机阶段II Hovon-126 / NMSG的结果结果来自21.13试验
3. Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial [J] . Zweegman Sonja, Schjesvold Fredrik H., van der Holt Bronno, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：IXAZOMIB-羟胺 - 低剂量地塞米松（ITD）诱导随后在新诊断的多发性骨髓瘤患者中与IXAZOMIB或安慰剂进行维持治疗，没有资格获得自体干细胞移植; 随机阶段II Hovon-126 / NMSG 21＃13试验结果
4. Interphase FISH of Chromosome 1 and 13 in Newly Diagnosed Myeloma and the Disease Prognosis [C] . Tian, Erming, Borset, Magne, Barlogie, Bart, International Conference on Biomedical Engineering and Informatics;BMEI '09 . 2009

机译：新诊断骨髓瘤的染色体1和13的相间FISH及疾病预后
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma [O] . Jesús F. San-Miguel, Maria-Asunción Echeveste Gutierrez, Ivan Špicka, 2018

机译：I / II期剂量递增研究研究在不适合移植的新诊断多发性骨髓瘤中全口口服依他佐米-美法仑-泼尼松诱导后单药依他佐米维持
7. Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open‐label, randomised, Phase III trial [O] . Graham H. Jackson, Charlotte Pawlyn, David A. Cairns, 2020

机译：在移植型无肢体瘤中的诱导和维持过程中优化免疫调节药物的价值：骨髓瘤XI，多期，开放标签，随机，第三阶段试验的结果

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

著录项

相似文献

相关主题

期刊订阅